Episode 11 – CRISPR with Dr Jakob Haaber, SNIPR Biome & Dr Richard Fox, Infinome Biosciences
Posted: 8 August 2022 | Drug Target Review | No comments yet
Join leading experts as they discuss the wide range of uses for CRISPR, including for therapeutics and biomanufacturing.
In this podcast, in partnership with Molecular Devices, we cover CRISPR in therapeutic settings and in pharmaceutical discovery with experts Dr Jakob Haaber, Vice President & Head of Delivery Technologies, SNIPR Biome and Dr Richard Fox, Co-Founder, CEO and CTO of Infinome Biosciences.
Tune in to hear about how CRISPR edits genes, how it can be applied to both industrial bioproduction and microbiome engineering and why this field is yet to see more exciting innovation!
Key learning points:
- What CRISPR is and how it can be applied therapeutically and for pharmaceutical discovery
- The potential of targeting the microbiome with CRISPR-based precision medicines
- How to accelerate biomanufacturing processes
- The advantages of CRISPR and recent developments
- Important considerations for gene editing
- The future of CRISPR and how gene editing workflows are evolving.
Make sure you don’t miss any new podcasts from Drug Target Review – sign up here to be notified of releases!
Dr Jakob Krause Haaber is Vice President of CRISPR & Delivery Technologies at SNIPR Biome. He holds a PhD in molecular microbiology and he is leading the engineering teams that build SNIPR Biome’s CRISPR based biological constructs with the aim of creating medicines to treat human disease.
Dr Richard Fox is Co-Founder, CEO and CTO of Infinome Biosciences. He has two decades of experience and innovation at the intersections of mathematics, computation, statistics and biology. Before joining Infinome, he was Executive Director – Data Science at
Related topics
Biopharmaceuticals, CRISPR, Gene Therapy, Genetic Analysis, Genome Editing, Genomics, Microbiology, Microbiome, Precision Medicine
Related organisations
Molecular Devices
